Correlating Genomic AMD Risk Variants with Lipid Composition and Phagocytic Function of Patient-Derived Induced Pluripotent Stem Cell (iPSC)-derived Retinal Pigment Epithelium (RPE)
将基因组 AMD 风险变异与患者来源的诱导多能干细胞 (iPSC) 来源的视网膜色素上皮 (RPE) 的脂质成分和吞噬功能相关联
基本信息
- 批准号:10701841
- 负责人:
- 金额:$ 39.35万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-30 至 2025-08-31
- 项目状态:未结题
- 来源:
- 关键词:Age related macular degenerationAntibodiesApicalBackBasal laminaBiological AssayBiological MarkersBlindnessBlood-Retinal BarrierCell LineCell PolarityCell membraneCellsCharacteristicsChoroidal NeovascularizationClinicalClustered Regularly Interspaced Short Palindromic RepeatsCollecting CellCoupledCulture MediaDataDefectDepositionDevelopmentDiseaseDocosahexaenoic AcidsDrusenElectroretinographyElectrospray IonizationEndocytosisEnzymesEventExhibitsExocytosisEyeEye diseasesFatty AcidsFluorescenceFunctional disorderGene Expression ProfileGenomicsGrowth FactorHealthHeterogeneityHomeostasisHumanImmunohistochemistryIn VitroInflammatoryInflammatory ResponseLaboratoriesLeadLightLinkLipidsLiquid ChromatographyMeasuresMembraneMethodsModelingMolecularMutationNaturePathogenesisPathologyPatientsPhagocytesPhagocytosisPhotoreceptorsPigmentsPlayPolyunsaturated Fatty AcidsPredisposing FactorProteinsRPE65 proteinRecyclingResistanceRetinaRod Outer SegmentsRoleSamplingSignal TransductionSourceStainsStructure of retinal pigment epitheliumSystemTight JunctionsU-Series Cooperative AgreementsVisionWestern Blottingage relatedcell typechromophorecomplement C3 precursordifferential expressionexperimental studygenetic variantgeographic atrophyhigh riskinduced pluripotent stem cellinflammatory modulationknockout genelipid metabolismlipidomicsmass spectrometermolecular markermolecular phenotypenovelnovel therapeutic interventionnovel therapeuticsparticipant enrollmentphotoreceptor degenerationpotential biomarkerprognostic indicatorreceptor bindingretinal rodsrisk varianttooltranscriptome sequencingtranscriptomicsvisual cycle
项目摘要
PROJECT SUMMARY
Age-related macular degeneration (AMD) is one of the leading causes of blindness worldwide. Dysfunction of
the retinal pigment epithelium (RPE) is one of the primary early events during AMD. RPE cells play many
important roles in vision and helps to maintain the health and integrity of the retina and defects in this layer lead
to progressive degeneration of photoreceptor cells. Hallmarks of AMD include protein deposits called drusen
which lie underneath the retinal pigment epithelium (RPE) and can evolve into geographic atrophy or choroidal
neovascularization with consequent loss of photoreceptors. While treatments exist that slow down the course of
some forms of AMD, a permanent cure to stop the inexorable loss of vision does not exist. A critical need in the
field is a better model for early features of AMD such as drusen formation and recognition of disease-causing
mechanisms is needed. This is a difficult problem given the multifactorial nature of AMD. It is well known that
photoreceptor and retinal pigment epithelial (RPE) cells are crucially dependent on tightly controlled lipid
homeostasis to maintain function. Each day, roughly a tenth of the rod outer segments (OS) are shed and
phagocytized by the RPE, which recycle the membranes as part of the visual cycle. Given the vast amount of
cell membrane, mostly comprised of lipids and proteins that is recycled daily, it is plausible that defects in lipid
metabolism could be involved in at least some part of the disease pathology. In this project we propose to study
lipidomics in human RPE cells from patient derived iPSCs as part of the Age-Related Eye Disease Study 2
(AREDS2) which aims to identify predisposing factors, clinical features, and prognostic indicators of AMD. We
propose to differentiate iPSC lines from this study, assess potential variability between lines, and evaluate
transcriptional differences. We will then assess differences in the lipid content of ‘disease’ versus control lines
searching for potential biomarkers of disease. Lastly, we will explore functional differences between lines by
performing phagocytosis assays. Together, we hope to identify novel disease-associated biomarkers that may
ultimately lead to new therapeutic options for treating this devastating disease.
项目总结
老年性黄斑变性(AMD)是世界范围内导致失明的主要原因之一。失调症
视网膜色素上皮(RPE)是AMD的主要早期事件之一。RPE细胞发挥了许多作用
在视觉中的重要作用,并有助于保持视网膜的健康和完整性,这一层的缺陷导致
光感受器细胞的进行性退化。AMD的特征包括一种名为玻璃体的蛋白质沉积
位于视网膜色素上皮(RPE)下面,可演变为地理性萎缩或脉络膜
导致光感受器丧失的新生血管。虽然有治疗方法可以延缓糖尿病的进程
某些形式的AMD,一种阻止不可避免的视力丧失的根治方法并不存在。中国的一项迫切需要
FIELD是研究AMD早期特征的较好模型,如玻璃体形成和对致病因素的识别
机制是必要的。考虑到AMD的多因素性质,这是一个难题。众所周知,
光感受器和视网膜色素上皮(RPE)细胞关键依赖于严格控制的脂质
维持功能的动态平衡。每天,大约十分之一的棒外节段(OS)被脱落和
被RPE吞噬,作为视觉循环的一部分,RPE循环膜。考虑到大量的
细胞膜,主要由每天循环使用的脂类和蛋白质组成,有可能是脂类缺陷
新陈代谢可能至少参与了疾病病理的某些部分。在这个项目中,我们建议研究
作为年龄相关性眼病研究2的一部分,患者来源的人视网膜色素上皮细胞的脂类组学
(AREDS2),旨在确定AMD的易感因素、临床特征和预后指标。我们
建议从这项研究中区分IPSC品系,评估品系之间的潜在变异性,并评估
转录差异。然后,我们将评估“疾病”与对照品系的脂肪含量的差异。
寻找潜在的疾病生物标志物。最后,我们将通过以下方式探讨行之间的功能差异
进行吞噬试验。我们希望共同识别新的疾病相关生物标志物,这些生物标志物可能
最终导致治疗这种毁灭性疾病的新的治疗选择。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Dorota Skowronska-Krawczyk其他文献
Dorota Skowronska-Krawczyk的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Dorota Skowronska-Krawczyk', 18)}}的其他基金
Correlating Genomic AMD Risk Variants with Lipid Composition and Phagocytic Function of Patient-Derived Induced Pluripotent Stem Cell (iPSC)-derived Retinal Pigment Epithelium (RPE)
将基因组 AMD 风险变异与患者来源的诱导多能干细胞 (iPSC) 来源的视网膜色素上皮 (RPE) 的脂质成分和吞噬功能相关联
- 批准号:
10576719 - 财政年份:2022
- 资助金额:
$ 39.35万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 39.35万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 39.35万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 39.35万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 39.35万 - 项目类别:
Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 39.35万 - 项目类别:
Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 39.35万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 39.35万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
- 批准号:
10639161 - 财政年份:2023
- 资助金额:
$ 39.35万 - 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
- 批准号:
10752441 - 财政年份:2023
- 资助金额:
$ 39.35万 - 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
- 批准号:
10867639 - 财政年份:2023
- 资助金额:
$ 39.35万 - 项目类别: